{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:25:07Z","timestamp":1792959907273,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK54759"],"award-info":[{"award-number":["DK54759"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016616","name":"Cystic Fibrosis Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015515","name":"Roy J. and Lucille A. Carver College of Medicine, University of Iowa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.rmed.2025.108478","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:31:51Z","timestamp":1763346711000},"page":"108478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Theratyping as a tool to guide clinical decision-making in patients with suspected cystic fibrosis and variants currently ineligible for CFTR modulator therapy"],"prefix":"10.1016","volume":"250","author":[{"given":"Ryan M.","family":"Gannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Bettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Teresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahuanty","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-2925","authenticated-orcid":false,"given":"Ian M.","family":"Thornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-201X","authenticated-orcid":false,"given":"Tayyab","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-5109","authenticated-orcid":false,"given":"Alejandro A.","family":"Pezzulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.108478_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency \u201cco-potentiator\u201d therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.rmed.2025.108478_bib3","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2025.108478_bib4","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108478_bib5","article-title":"Characterization of an ex vivo model of human airway epithelium","volume":"54","author":"Horton","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108478_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56737-9","article-title":"An optimized, robust and reproducible protocol to generate well-differentiated primary nasal epithelial models from extremely premature infants","volume":"9","author":"Martens","year":"2019","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.rmed.2025.108478_bib7","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.rmed.2025.108478_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-61779-117-8_4","article-title":"Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators","volume":"741","author":"Neuberger","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108478_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2025.108478_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial","volume":"12","author":"Solomon","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108478_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26955","article-title":"Response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis with the N1303K mutation: case report and review of the literature","volume":"10","author":"Tupayachi Ortiz","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.rmed.2025.108478_bib12","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.108478_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1471-0528.2000.tb11697.x","article-title":"The outcome of 72 pregnancies in 55 women with cystic fibrosis in the United Kingdom 1977\u20131996","volume":"107","author":"Edenborough","year":"2000","journal-title":"BJOG"},{"issue":"13","key":"10.1016\/j.rmed.2025.108478_bib14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/1471-0528.16423","article-title":"The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study","volume":"127","author":"Ashcroft","year":"2020","journal-title":"BJOG"},{"issue":"9","key":"10.1016\/j.rmed.2025.108478_bib15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/gtmb.2016.0102","article-title":"Phenotypes of California CF newborn screen-positive children with CFTR 5T allele by TG repeat length","volume":"20","author":"Salinas","year":"2016","journal-title":"Genet. Test. Mol. Biomark."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:53:05Z","timestamp":1773931985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125005414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":14,"alternative-id":["S0954611125005414"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108478","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theratyping as a tool to guide clinical decision-making in patients with suspected cystic fibrosis and variants currently ineligible for CFTR modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108478"}}